Login to Your Account

Pharma: Clinic Roundup

Thursday, July 19, 2012
• GlaxoSmithKline plc, of London, said it began a Phase III trial of its herpes zoster vaccine candidate for the prevention of shingles in immunocompromised patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription